Upregulated miR-27a-3p Indicates a Poor Prognosis in Pancreatic Carcinoma Patients and Promotes the Angiogenesis and Migration by Epigenetic Silencing of GATA6 and Activating VEGFA/VEGFR2 Signaling Pathway
Authors:
Open Access
- 1 December 2019
- journal article
- retracted article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 12, 11241-11254
Abstract
Background: Abnormal miR-27a-3p expression has been frequently reported in several types of human cancer and contributes to tumor progression. However, the role and potential molecular mechanism of miR-27a-3p in the progression of pancreatic carcinoma have not been clarified. Materials and methods: The expression of miR-27a-3p and GATA binding protein 6 (GATA6) in pancreatic carcinoma tissues and cell lines was evaluated by quantitative real-time PCR and Western blotting analysis. The relationship between clinical pathologic features and miR-27a-3p expression was analyzed with Chi-square test. The regulatory mechanism of miR-27a-3p on GATA6 was confirmed by luciferase reporter assay and bioinformatics analysis. The effects of miR-27a-3p by targeting GATA6 on cell angiogenesis and migration were assessed by capillary tube formation and wound healing assays. Results: MiR-27a-3p expression was significantly upregulated in pancreatic carcinoma tissues and cell lines. Highly expressed miR-27a-3p was closely related to more lymph node metastasis, present peritoneal metastasis, and poor prognosis in patients with pancreatic carcinoma. MiR-27a-3p promoted migration and angiogenesis of pancreatic carcinoma cells by activating vascular endothelial growth factor A (VEGFA) and vascular endothelial growth factor receptor 2 (VEGFR2) expression. A significantly negative correlation between GATA6 mRNA and miR-27a-3 expression was found in pancreatic carcinoma samples. Modulation of miR-27a-3p could alter GATA6 expression in pancreatic carcinoma cells. GATA6 was identified as a functional target gene of miR-27a-3p, and GATA6 knockdown partially reversed the effects of miR-27a-3p siliencing on the migration and angiogenesis of pancreatic carcinoma cells by regulation of VEGFA/VEGFR2 pathway. Conclusion: Upregulated miR-27a-3p indicates a poor prognosis in pancreatic carcinoma patients and promotes the angiogenesis and migration by epigenetic silencing of GATA6 and activating VEGFA/VEGFR2 signaling pathway, and indicating miR-27a-3p may be a promising therapeutic target for pancreatic carcinoma treatment.Keywords
This publication has 35 references indexed in Scilit:
- Therapeutic options for the management of pancreatic cancerWorld Journal of Gastroenterology, 2014
- MiR-200c Increases the Radiosensitivity of Non-Small-Cell Lung Cancer Cell Line A549 by Targeting VEGF-VEGFR2 PathwayPLOS ONE, 2013
- Combined Serum CA19-9 and miR-27a-3p in Peripheral Blood Mononuclear Cells to Diagnose Pancreatic CancerCancer Prevention Research, 2013
- miR-24-3p and miR-27a-3p promote cell proliferation in glioma cells via cooperative regulation of MXI1International Journal of Oncology, 2012
- Pancreatic cancerThe Lancet, 2011
- Advanced pancreatic carcinoma: current treatment and future challengesNature Reviews Clinical Oncology, 2010
- MicroRNAs: Target Recognition and Regulatory FunctionsCell, 2009
- Genomic Profiling Identifies GATA6 as a Candidate Oncogene Amplified in Pancreatobiliary CancerPLOS Genetics, 2008
- MicroRNA Signatures in Human CancersNature Reviews Cancer, 2006
- Molecular pathogenesis of pancreatic cancerBest Practice & Research Clinical Gastroenterology, 2006